Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Paediatrics · Pediatrics · 2026-10-01

Five systematic reviews (60 studies) for the AAP UTI guideline, low to very low certainty: ≤7-day antibiotics may not raise recurrence; oral may match parenteral; prophylaxis (in reflux or bowel/bladder problems) may not cut breakthrough UTI or scarring but may raise resistance.

Meta-analysisn = 60 studies
AlShenaiber et al. A Systematic Review and Meta-Analysis of the Prevention and Management of Pediatric Urinary Tract Infection and Suspected Urinary Tract Infection: Technical Report
Paediatrics · Pediatrics · 2026-10-01

AAP technical report for the 2026 UTI guideline (children 8 days–5 years): the revised UTI definition requires pyuria, with thresholds by age and whether cultures are pending, and positive-culture criteria now vary by age and collection method.

Guideline
Forster et al. Urinary Tract Infection Diagnosis-A Companion to the American Academy of Pediatrics' 2026 Clinical Practice Guideline on the Diagnosis and Management of Urinary Tract Infection: Technical Report
Paediatrics · Pediatrics · 2026-10-01

In a meta-analysis of 90 studies of children after urinary tract infection, renal and bladder ultrasound detected vesicoureteral reflux poorly: after a first UTI, sensitivity 50%, specificity 71%; not substantially better for high-grade reflux (66%) or recurrent UTI.

Meta-analysisn = 90 studies
Azzam et al. A Systematic Review and Meta-Analysis of the Role of Ultrasonography for the Diagnosis of Vesicoureteral Reflux in Pediatric Patients Following Urinary Tract Infections: Technical Report
Paediatrics · Lancet Child Adolesc Health · 2026-09-08

In extended follow-up of a South African trial in HIV-unexposed infants, PCV13 1+1 schedules (primed at 6 or 14 weeks) stayed non-inferior to 2+1 for antibody levels to age 5 years; PCV10 1+1 schedules failed non-inferiority at 4 and 5 years.

RCTn = 354
Kapelus et al. Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.